# US 2024/0390428 A1 · Salmonella strain for prevention and treatment of cancer and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0390428 A1
- Document ID: US20240390428A1
- Status: Published application
- Kind: A1
- Application number: 18/252,268
- Filed: 2021-11-09
- Published: 2024-11-28
- Earliest claimed: 2020-11-09
- Assignees: Cncure Biotech Inc.
- Applicants: CNCure Biotech, Inc.
- Inventors: Jung-Joon Min; Yeongjin Hong; Sung-Hwan You; Nguyen Dinh Huy
- Web page: https://patentgrep.com/patent/US20240390428A1

## CPC

- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- C07K 14/195: from bacteria
- C07K 14/245: Escherichia (G)
- C07K 14/255: Salmonella (G)
- C12N 15/74: Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2830/003: tet inducible
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present disclosure relates to a DNA construct, and a strain into which a recombinant vector comprising the DNA construct has been introduced. The DNA construct according to the present disclosure allows the expression of anticancer genes, operably linked downstream of first and second promoters, in a host strain or cell, to prevent and treat cancer. In addition, the DNA construct of the present invention can control the treatment of doxycycline so that the anticancer protein can be expressed at an appropriate dose for cancer treatment.

## Claims

### Claim at position 1

1-18. (canceled)

### Claim 19

A DNA construct comprising:
a gene encoding a first protein and a second protein, wherein the first protein is flagellin and the second protein is a toxin protein; and
a first promoter and a second promoter corresponding thereto.

### Claim 20 (depends on 19)

The DNA construct of claim 19, wherein the flagellin is flagellin A or flagellin B.

### Claim 21 (depends on 19)

The DNA construct of claim 19, wherein the toxin protein is at least one selected from the group consisting of ricin, saporin, gelonin, momordin, debouganin, diphtheria toxin, Pseudomonas toxin, hemolysin (HlyA), FAS ligand (FASL), tumor necrosis factor-α (TNF-α), TNF-related apoptosis-inducing ligand (TRAIL), streptolysin O (SLO), pneumolysin (PLO) listeriolysin (LLO), and cytolysin A (ClyA).

### Claim 22 (depends on 19)

The DNA construct of claim 19, further comprising a gene encoding a regulatory protein.

### Claim 23 (depends on 22)

The DNA construct of claim 22, wherein the regulatory protein is a TetR protein.

### Claim 24 (depends on 19)

The DNA construct of claim 19, wherein the first promoter is a tetA promoter, and the second promotor is a tetR promoter.

### Claim 25 (depends on 19)

A recombinant vector comprising the DNA construct of claim 19.

### Claim 26 (depends on 25)

A strain into which the recombinant vector of claim 25 has been introduced.

### Claim 27 (depends on 26)

The strain of claim 26, wherein the strain is at least one selected from the group consisting of a Salmonella sp. strain, a Clostridium sp. strain, a Bifidobacterium sp. strain, and an E. coli strain.

### Claim 28 (depends on 26)

A pharmaceutical composition for preventing or treating cancer comprising the strain of claim 26 as an active ingredient.

### Claim 29 (depends on 28)

The pharmaceutical composition of claim 28, wherein the cancer is at least one selected from the group consisting of melanoma, fallopian tube cancer, brain cancer, small intestine cancer, esophageal cancer, lymph gland cancer, gallbladder cancer, blood cancer, thyroid cancer, endocrine cancer, oral cancer, liver cancer, biliary tract cancer, colon cancer, rectal cancer, cervical cancer, ovarian cancer, kidney cancer, stomach cancer, duodenum Cancer, prostate cancer, breast cancer, brain tumor, lung cancer, undifferentiated thyroid cancer, uterine cancer, colon cancer, bladder cancer, ureter cancer, pancreatic cancer, bone/soft tissue sarcoma, skin cancer, non-Hodgkin's lymphoma, Hodgkin's lymphoma, multiple myeloma, leukemia, myelodysplastic syndrome, acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, and solitary myeloma.

### Claim 30 (depends on 28)

The pharmaceutical composition of claim 28, wherein the pharmaceutical composition inhibits growth or metastasis of cancer.

### Claim 31

A strain into which a recombinant vector has been introduced, the recombinant vector comprising:
a first DNA construct including a gene encoding a first protein and a first promoter corresponding thereto, wherein the first protein is flagellin; and
a second DNA construct including a gene encoding a second protein and a second promoter corresponding thereto, wherein the second protein is a toxin protein.

### Claim 32 (depends on 31)

A pharmaceutical composition for preventing or treating cancer comprising the strain of claim 31 as an active ingredient.

### Claim 33

A pharmaceutical composition for preventing or treating cancer comprising as active ingredients:
flagellin or a nucleotide encoding the same; and
a toxin protein or a nucleotide encoding the same.

### Claim 34 (depends on 26)

A method for preventing or treating cancer by administering an effective amount of the strain of claim 26 to a target subject.

### Claim 35 (depends on 31)

A method for preventing or treating cancer by administering an effective amount of the strain of claim 31 to a target subject.

### Claim 36

A method for preventing or treating cancer by administering effective amounts of a strain expressing exogenous flagellin and a strain expressing exogenous toxin protein to a subject in combination.
